5:49 PM
 | 
Apr 07, 2009
 |  BC Extra  |  Company News

Epix announces MS-325 deal, exchange offer

Epix Pharmaceuticals Inc. (NASDAQ:EPIX) sold U.S., Canadian and Australian rights to MS-325 (formerly Vasovist gadofosveset) to diagnostic company Lantheus Medical Imaging Inc. (North Billerica, Mass.) for $28 million in cash....

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >